Maviret 100/40 mg glecaprevir–pibrentasvir film‑coated Tablets × 84

MAVIRET is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult and pediatric patients 3 years and older with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).

How to use:

• Adults: Three tablets taken at the same time orally once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) with food.
• Pediatric Patients 3 Years to Less than 12 Years Old: Dosing is based on weight.

Caution & Warnings:

• Risk of Hepatitis B Virus Reactivation
• Risk of Hepatic Decompensation/Failure in Patients with Evidence of Advanced Liver Disease

Side Effects:

• Headache
• Fatigue

Ingredients:

• glecaprevir and pibrentasvir 100Mg/40Mg.